Skip to content
Education Use Only
For educational use only — The physician’s written order and the unit protocol always govern
Medical Associates  ·  Department of Nephrology ← Nursing cards  ·  Maintenance Hemodialysis  ·  urinenephrology.org
Dialysis Nursing Reference Card  ·  Maintenance Hemodialysis

N19 — Dialysis Adequacy and Quality Review

The monthly adequacy result, recurrent shortened sessions, or symptoms despite an acceptable Kt/V.
Andrew Bland, MD, FACP, FAAP Updated September 2026 Prints on one sheet, front and back
N19 — Dialysis Adequacy and Quality Review FRONT
Front · at the chair

When: The monthly adequacy result, recurrent shortened sessions, or symptoms despite an acceptable Kt/V.

Do this

  1. Confirm sampling technique and timing for pre/post urea. Compare delivered treatment time with the prescription and identify missed or shortened sessions.
  2. Review blood-flow delivery, repeated alarms, interruptions, access findings, and recent access procedures when Kt/V falls.
  3. For conventional three-times-weekly HD, distinguish the KDOQI target spKt/V of 1.4 from the minimum delivered value of 1.2 [1]. Report results below the prescribed goal.
  4. Review symptoms, volume tolerance, recovery time, intake/weight change, function, and the patient's own priorities alongside adequacy.

Call / escalate

  • An unexplained fall or result below target, recurrent inability to complete treatment, or an abnormal access examination: arrange prompt team review.
  • Breathlessness, chest pain, confusion, arrhythmia symptoms, or acute access failure: use the urgent clinical pathway; do not wait for monthly rounds.

Don't

  • Do not shorten prescribed treatment because Kt/V is above a threshold.
  • Do not apply a per-session spKt/V target to a different dialysis schedule without the nephrologist's prescription, or change blood flow, time, or dialyzer independently.
N19 — Dialysis Adequacy and Quality Review BACK
Back · why, and the evidence

Why

  • Kt/V describes urea clearance. It does not measure every treatment goal or capture how a patient feels [1,2].
  • The HEMO trial did not find an overall survival benefit from increasing the small-solute dose above the standard-dose arm. Meeting a minimum is necessary; chasing a higher number is not a complete quality plan [2].
  • A meaningful review connects the result to delivered treatment, access performance, safety, nutrition, symptoms, and patient goals.

Bring this to the review

Prescription and actual minutes; sampling method; Kt/V trend; missed sessions; blood-flow/pressure alarms; access findings; symptoms and recovery time; barriers and a specific follow-up plan.

Go deeper

References

  1. KDOQI Hemodialysis Adequacy: 2015 Update. PMID: 26498416
  2. HEMO trial. N Engl J Med. 2002. PMID: 12490682

Adapted from the linked Clinical Mastery reviews; updated September 27, 2026. For education; the physician's written order and the unit protocol always govern.